UCL is making significant progress in developing cell and gene therapies which are transforming treatment for patients, according to a new report from the UCL Translational Research Office and UCL Business.
The Success: From Lab to Market 2026 report, presented at the UCL Advanced Therapies Symposium on 22 April, outlines a portfolio of more than 50 discovery projects, 29 preclinical and IND-enabling programmes preparing therapies for first-in-human clinical trials, and 30 Phase I/II clinical trials. This work is supported by over £70 million in public funding alongside private investment. In this last year alone, one therapy - a CAR-T immonutherapy for Acute Lymphoblastic Leukaemia - got regulatory approval and is now available to NHS patients while four therapies have progressed from the preclinical stage into Phase I/II clinical trials in the past year.
